Bortezomib and Bevacizumab ("BB-Mib-Mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC).

Trial Profile

Bortezomib and Bevacizumab ("BB-Mib-Mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC).

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Bortezomib (Primary)
  • Indications Renal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Apr 2017 Planned End Date changed from 1 Jun 2017 to 21 Aug 2018.
    • 06 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Jun 2017, as reported by ClinicalTrials.gov.
    • 06 Apr 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top